ArticleBMC biology2026
Decoding the association between platinum resistance and HPV status in cervical cancer using organoid models.
Article in BMC biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCervical cancer remains a leading cause of cancer-related mortality in women, with high-risk HPV types (16, 18, 31, 33, 45, 52, and 58) playing a key role in its development. Platinum-based chemotherapy is standard for recurrent or metastatic cervical cancer, but platinum resistance remains a major challenge. The link between HPV infection and platinum resistance is not well understood. Tumor organoids offer a physiologically relevant model for investigating drug resistance mechanisms in cervical cancer.
resultsWe successfully established 37 cervical cancer organoids (CCOs), with 27 expanded for characterization and drug sensitivity testing. CCOs recapitulated the biomarker expression patterns and genomic features of their corresponding tissues. Drug sensitivity assays revealed increased cisplatin/carboplatin resistance in the non-HPV16 high-risk HPV CCOs subgroup, compared to HPV-negative CCOs. Single-cell RNA sequencing identified diverse cellular populations within CCOs, with platinum-resistant CCOs showing enhanced DNA repair, activation of the PI3K/AKT pathway, and suppressed apoptotic signaling. We also found that the PI3K/AKT inhibitor BYL719 enhanced the response to cisplatin and carboplatin in non-HPV16 high-risk HPV CCOs but not in HPV-negative CCOs.
conclusionsCervical cancer organoids faithfully replicate the histopathological and genomic characteristics of their parental tumors, demonstrating their potential as preclinical models for studying cancer progression and drug resistance. Our findings suggest that the non-HPV16 high-risk HPV infections may contribute to increased platinum resistance through enhanced DNA repair mechanisms, increased PI3K/AKT activation and suppressed apoptosis, providing new insights for personalized cervical cancer treatment. The PI3K/AKT inhibitor BYL719 may serve as a potential therapeutic adjunct to enhance platinum efficacy in those patients with platinum-resistant cervical cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.